98%
921
2 minutes
20
Metronidazole is a nitroimidazole antibacterial and antiprotozoal drug with bacteriocidal activity against a broad range of anaerobic bacteria. It is a recognized treatment for elephants diagnosed with anaerobic bacterial infection or protozoal disease or exhibiting signs of colonic impaction, diarrhea, and colic. This study evaluated the pharmacokinetics of rectally administered metronidazole (15 mg/kg) in five adult female Asian elephants (Elephas maximus). Serum samples were collected from each animal for 96 hr after rectal administration of metronidazole. Serum concentrations of metronidazole and its primary metabolite, hydroxymetronidazole, were measured via ultraperformance liquid chromatography. Data were analyzed via a noncompartmental pharmacokinetic approach. Results indicated that serum levels of metronidazole were quantifiable at the 0.25 hr time point and absent in all elephants by the 96 hr time point. The serum peak concentration (mean ± SD, 13.15 ± 2.59 μg/ml) and area under the curve from time 0 to infinity (mean ± SD, 108.79 ± 24.77 hr × μg/ml) were higher than that reported in domestic horses after similar usage. Concurrently, the time of maximum serum concentration (mean ± SD, 1.2 ± 0.45 hr) and terminal elimination half-life (harmonic mean ± pseudo-SD, 7.85 ± 0.93 hr) were longer when compared to equine reports. Rectal administration of metronidazole was well tolerated and rapidly absorbed in all study elephants. Based on the findings in this study, metronidazole administered at a single dose of 15 mg/kg per rectum in the Asian elephant is likely to result in serum concentrations above 4 μg/ml for 8 hr and above 2 μg/ml for 24 hr after treatment is administered. Dosing recommendations should reflect the mean inhibitory concentration of metronidazole for each pathogen.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1638/2015-0160.1 | DOI Listing |
IJU Case Rep
September 2025
Department of Urology Toyama University Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama Toyama Japan.
Introduction: The association between the risk of latent tuberculosis infection (LTBI) reactivation and immune checkpoint inhibitor (ICI) administration has been reported.
Case Presentation: A man in his seventies underwent robot-assisted laparoscopic radical cystectomy with ileal conduit diversion for muscle-invasive bladder cancer. Three years postoperatively, CT revealed metastases to the para-aortic lymph nodes and rectum.
Iran J Basic Med Sci
January 2025
Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Objectives: Ulcerative colitis (UC) is an inflammatory disorder that is managed with various treatments, which have varying degrees of effectiveness and side effects, highlighting the need for new and more effective alternatives. In this study, we applied Artrestan (Sacubitrol/Valsartan), which has potent anti-inflammatory properties, alone or in combination with mesalazine, in the treatment of UC animal models.
Materials And Methods: Thirty male rats were randomly divided into control, colitis, Artrestan (60 mg/kg/day), mesalazine (100 mg/kg/day), and Artrestan plus mesalazine groups.
Electrolyte depletion syndrome (EDS), also known as McKittrick-Wheelock syndrome, is a rare but life-threatening condition caused by secretory diarrhea from colorectal villous tumors, often accompanied by severe electrolyte imbalances and renal dysfunction. Large, circumferential tumors have traditionally been managed with surgical resection, frequently requiring stoma formation. Recently, endoscopic submucosal dissection (ESD) has emerged as a minimally invasive alternative, although its feasibility for large rectal tumors remains limited.
View Article and Find Full Text PDFJAC Antimicrob Resist
August 2025
Division of Medical Microbiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Objectives: Evaluation of differences in the intestinal microbiome and resistome among high-risk patients (i.e. intensive care, oncology, transplant recipients) who are and are not colonized with carbapenem-resistant Enterobacterales (CRE).
View Article and Find Full Text PDFBMJ Open Gastroenterol
August 2025
Susan and Leonard Feinstein IBD Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Objective: Bothersome ulcerative colitis (UC) symptoms include stool frequency (SF), rectal bleeding (RB), abdominal pain and bowel urgency; symptomatic relief is a key treatment goal. Etrasimod is an oral, once-daily (QD), selective sphingosine 1-phosphate receptor modulator for the treatment of moderately to severely active UC. We assessed outcomes related to symptomatic relief among patients with moderately to severely active UC in the phase III ELEVATE UC clinical programme.
View Article and Find Full Text PDF